biohack.The longevity wire
LIVE WIREUpdated · scanning every 6 hours
22:17 Gene therapy improved swallowing in all 9 patients so far, maker says✦22:16 Taurine helps keep aging inflammation in check in lab tests, study finds✦22:13 Boosting one protein left old mice less frail and living 14% longer✦22:13 Adding a drug to Keytruda halved death risk in a head and neck cancer trial✦22:10 US lets pharmacies make 6 unapproved peptides for now, despite FDA doubts✦16:30 Older adults who nap most days had a 48% higher dementia risk, study finds✦16:28 Study ties weaker muscles in old age to faulty nerve-to-muscle signals✦16:23 Lilly says experimental shot beat Ozempic with over double the weight loss✦22:17 Gene therapy improved swallowing in all 9 patients so far, maker says✦22:16 Taurine helps keep aging inflammation in check in lab tests, study finds✦22:13 Boosting one protein left old mice less frail and living 14% longer✦22:13 Adding a drug to Keytruda halved death risk in a head and neck cancer trial✦22:10 US lets pharmacies make 6 unapproved peptides for now, despite FDA doubts✦16:30 Older adults who nap most days had a 48% higher dementia risk, study finds✦16:28 Study ties weaker muscles in old age to faulty nerve-to-muscle signals✦16:23 Lilly says experimental shot beat Ozempic with over double the weight loss
← All story threadsSTORY THREAD

Two-target antibody for head and neck cancer.

1 report so far. New developments are added to this thread as they happen.

  1. Oct 28, 2026
    BIG TRIAL REPORTS LONGER SURVIVAL WITH KEYTRUDATrial result · 699 enrolled

    Adding a drug to Keytruda halved death risk in a head and neck cancer trial

    A large trial of 699 people with advanced head and neck cancer reports longer survival when a two-target antibody was added to Keytruda. Full numbers have not been published yet.